Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Microvitality

Tufts spin-off with an IRB-approved ingestible capsule that samples small-intestine microbiome and contents non-invasively.

Cambridge, MA (also an office in Athens, Greece), United States, North AmericaMedTech & devices, Ingestible small intestine sampling capsule
Stage
Pre-seedNo documented AI
Product
PrototypeNone known
Funding raised
$10Kdisclosed
Founded
20242 years ago
Founders
5Zoe, Sofia…
Global score
3.5Grade DRank 111 of 151

Overview

Tufts University spin-off developing an ingestible capsule for non-invasive sampling of the small intestine's microbiome and contents.

Traction

None known

Capsule validated in 3 large animal models and NSR/IRB approved for human use; no customer or clinical trial announced yet.

Market

Microbiome diagnostics

Most microbiome data comes from stool, which poorly represents the small intestine where much digestion and absorption happens. Pharma, nutrition and probiotic companies, and gastroenterology researchers, need in-situ samples to prove mechanisms and claims. Buyers are R&D and clinical teams paying per study or per device; later, clinical diagnostics could follow. The market is emerging and evidence-led.

Addressable market

2025
$0.2B
2030
$0.3B
+13.4% a year

Microbiome diagnostics: $0.16bn in 2025 (TechSci) to ~$0.33bn in 2030 (CAGR 13.4%).

Customers

Probiotic, nutrition and pharma R&D teams; academic gastroenterology researchers

Who signs the cheque

Clinical research / R&D directors and principal investigators

Geographies

  • United States

Drivers

  • Microbiome science shifting to the small intestine
  • Need for evidence behind gut-health claims
  • Non-invasive alternative to endoscopy

Headwinds

  • Student team
  • Small diagnostic market
  • Regulatory path to clinical diagnostic use

Global microbiome diagnostics market of $0.16bn in 2025 (TechSci Research) and ~$0.33bn in 2030 (Global Industry Analysts, CAGR 13.4%): a still-emerging niche.

Scalability 5/10. Ingestible device subject to approval (FDA/CE) and clinical trials; laboratory analyses still to be industrialized.

Market source: techsciresearch.com

Technology

Category

Medical device (ingestible sampling capsule)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

prototype

How it works

A patented 3D-printed pill collects samples in situ in the small intestine. It was developed over ~8 years at Tufts and validated in three large animal models.

Moat

Moderate-strong: patents and years of academic development; NSR/IRB approval for human use.

Differentiation

Non-invasive small-intestine sampling versus stool tests or endoscopy.

Integration points

  • Sponsor clinical studies
  • Microbiome sequencing labs
  • Nutrition/probiotic R&D programmes

Depends on

  • Clinical study partners
  • Manufacturing scale-up
  • Lab analysis of samples

Use of AI

No use of AI mentioned

Product in detail

Patented 3D-printed pill that collects samples in situ in the small intestine (developed over ~8 years at Tufts).

Business

Model
Likely per-study sale of capsules and sampling services to sponsors (not yet commercial).
Revenue logic
Not disclosed.
Go-to-market
Academic and incubator networks (Tufts, MESH/Mass General Brigham).

Next milestones

  1. First human study with a paying sponsor
  2. Manufacturing partner
  3. Pre-seed round

Key risks

  • Student team
  • No revenue
  • Clinical adoption

Opportunities

3 found in the network

Concrete moves for Microvitality inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 2
  • Investors 1

Customers2

Who could buy, or sell through

Run a sponsored study on Nuhpro’s heat-resistant probiotic

Nuhpro must substantiate gut-health claims for its patented pre/probiotic formulations; Microvitality can show whether the probiotic reaches and acts in the small intestine. It would be Microvitality's first commercial sponsor and a reusable protocol for nutrition brands.

30%confidence

Evidence from the records

  • “Patented 3D-printed pill that collects samples in situ in the small intestine”
  • “including a heat-resistant probiotic”
  • “Health claims”
If it works
A paid pilot study and a case study to sell to other probiotic brands.
First step
Send Nuhpro a two-page study design with cost per participant.

Measure fat absorption in situ for Vytala’s malabsorption product

Vytala's lipid matrix aims to improve fat and nutrient absorption in the small intestine and may seek CMS reimbursement, which needs mechanistic evidence. Microvitality's capsule can sample intestinal contents directly.

25%confidence

Evidence from the records

  • “Proprietary structured crystallized lipid technology (Lym-X-Sorb® lipid matrix) that improves the absorption of fats and nutrients”
  • “the website states that reimbursement may be possible via CMS”
  • “NSR/IRB approved for human use”
If it works
A mechanistic study supporting Vytala's clinical dossier.
First step
Book an intro call with Vytala's CEO, Jim O'Connell, to discuss evidence gaps.

Investors1

A fund whose thesis fits

Join MassChallenge’s Boston HealthTech cohort

MassChallenge runs no-equity programmes for HealthTech and life-science start-ups in Boston, next to Tufts; network member Monte Caldera went through it. It would add mentors and pharma corporate partners.

30%confidence

Evidence from the records

  • “MassChallenge”
  • “Capsule validated in 3 large animal models”
If it works
Access to corporate sponsors and non-dilutive prize money.
First step
Ask Monte Caldera's founder about MassChallenge's next HealthTech application window.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

US federal agency funding startups through non-dilutive SBIR/STTR grants (America's Seed Fund); backed G-Space and BioSapien.

Tufts ingestible gut-sampling capsule validated in animals with IRB approval: high-risk biomedical innovation ideal for SBIR Phase I/II.

55%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “Capsule validated in 3 large animal models”
Intro path
G-Space founder (NSF grantee).
First step
Submit an NSF SBIR Project Pitch.

Zero-equity nonprofit accelerator (since 2009) running corporate-funded programmes in Boston, Dallas, Jerusalem, Lausanne and London.

US gut-sampling capsule with NIH grants — health/biotech at pre-seed.

45%confidence

Evidence from the records

  • “"HealthTech","Biotech & life sciences"”
  • “Ingestible small intestine sampling capsule”
  • “Capsule validated in 3 large animal models and NSR/IRB approved for human use”
Intro path
Founder-to-founder intro via Monte Caldera Technologies Inc. (network portfolio company of MassChallenge).
First step
Apply to the Boston health track.

Self-described most active pre-seed deep-tech investor, backing human and planetary health from pre-seed through follow-on rounds.

Tufts ingestible gut-sampling capsule with IRB approval: human-health deep tech hardware at pre-seed.

45%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “Capsule validated in 3 large animal models”
First step
Pitch with the first-in-human plan.

New York health-innovation company (since 2011) backing 500+ health founders in Moonshot communities: diagnostics, treatments, type 1 diabetes, Alzheimer's.

Ingestible small-intestine sampling capsule with IRB approval: a novel diagnostic tool from Tufts.

40%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Apply to the diagnostics community.

bioMérieux, French in-vitro diagnostics group, investing in MedTech and life sciences, including its Allergen Alert intrapreneurship spin-off.

Ingestible small-intestine sampling capsule, NSR/IRB-approved for human use: sampling feeds microbiology diagnostics. Pre-seed prototype.

35%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Pitch sample-to-diagnostic workflow integration.

Physician-founded Austin VC ($250M+ AUM) backing science-driven therapeutics, digital health, industrial biotech and climate companies.

US ingestible gut-sampling capsule — digital health/diagnostics.

35%confidence

Evidence from the records

  • “digital health”
  • “Ingestible small intestine sampling capsule”
  • “Capsule validated in 3 large animal models and NSR/IRB approved for human use”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send NIH-grant data.

US angel network investing at pre-seed and seed; part of Vytala Health's US$0.8M pre-seed.

Ingestible small-intestine sampling capsule: gut health adjacency to Vytala's malabsorption focus.

25%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “Pre-seed”
Intro path
Vytala Health (gut-health peer)
First step
Explore a joint gut-health narrative.

Investment arm linked to Protocol Labs; the only recorded data point is the oversubscribed $7.5M seed of brain-interface company Neurosoft.

Ingestible gut-sampling capsule from Tufts: frontier biomedical hardware at pre-seed, a loose analogue of the Neurosoft deal.

15%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Hold until PL Capital's mandate is confirmed.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption7.0/10
Business model1.0/10
Market3.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early.

Disruption

7/10

Ingestible small intestine sampling capsule: a new approach for microbiome research.

Business model

1/10

Validated in animal models, no customers.

Market

3/10

TAM microbiome diagnostics ~$0.156bn (base 3), medium scalability 5/10 (0), no proven international expansion (0) → 3/10.

Risk

8/10

Lower is better

High risk: student team, device regulation.

Strengths

  • Non-invasive approach
  • NSR/IRB approval

Risks

  • Student team
  • No revenue

Funding

$10K, disclosed
  1. 2024

    awardnot specified

    Tufts $100k New Ventures Competition

  2. 2025

    awardUSD 5,000

    MESH Incubator, Mass General Brigham

  3. mai 2025

    grantUSD 5,000

    Tufts / IDEA (Northeastern)

  4. antérieur

    research grant (NIH R21/R33)not specified

    NIH

Amount used in the study. $5K award + $5K grant; other awards and NIH grants not quantified.

Note. awards/grants only; no public equity round found

Site address: 700 Main Street, Cambridge, MA, and Athens. No SWC qualification found (not among the identified Boston/Harvard regional finalists).

Team

  • Zoe Watson

    CEO

    Student in Tufts' MS Innovation & Management (MSIM) program (Gordon Institute).

  • Sofia Paschenti

    COO

    MSIM student at Tufts; winner of the MESH Disruptive Innovation Prize 2025 (Mass General Brigham).

  • Julian Finney

    Member of the founding team

    MSIM student at Tufts.

  • Haobin Li

    Member of the founding team

    MSIM student at Tufts.

  • Dr Sameer Sonkusale

    Partner researcher (technology)

    Professor at Tufts, PI on the NIH grants for microbiome sampling capsules.

Sources

Identification confidence
medium
Founding year: 2024 (low confidence)
Site first archived in 2024, proxy (year the site existed, no confirmed founding date); born at the Tufts Gordon Institute (MSIM program), technology developed over ~8 years in the Sonkusale lab web.archive.org
  1. 1microvitalitybio.com/
  2. 2gordon.tufts.edu/news-events/news/putting-innovation-work-get-know-microvita
  3. 3caplight.com/company/microvitalitybio
  4. 4gordon.tufts.edu/news-events/news/winners-announced-2024-tufts-100k-new-vent

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet